Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical stage immuno-oncology company, renowned for its innovation in next-generation cancer immunotherapies. Headquartered in Gaithersburg, MD, Sensei leverages its proprietary TMAb™ (Tumor Microenvironment Activated biologics) platform to develop cutting-edge therapeutics designed to harness the body's immune system against cancer. The company’s leading product candidates include SNS-101, SNS-102, SNS-103, and SNS-201, all of which are conditionally active antibodies targeting different immunosuppressive markers within the tumor microenvironment.
Sensei’s flagship candidate, SNS-101, is designed to block the VISTA (V-domain Ig suppressor of T cell activation) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. SNS-101 is currently undergoing a multi-center Phase 1/2 clinical trial, evaluating its safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy as both a monotherapy and in combination with Regeneron's PD-1 inhibitor, Libtayo® (cemiplimab), in patients with advanced solid tumors. Initial data are promising, showing SNS-101 to be well-tolerated and demonstrating clinical activity, particularly in tumor types typically resistant to PD-1 monotherapy.
Other promising candidates include SNS-102, targeting VSIG-4 (V-Set and Immunoglobulin Domain Containing 4), and SNS-103, targeting CD39 (ecto-nucleoside triphosphate diphosphohydrolase-1), as well as SNS-201, a conditionally active VISTAxCD28 bispecific antibody. The company has established key academic collaborations, including with Brown University, to bolster its research and development efforts.
Financially, Sensei maintains a strong balance sheet with cash reserves projected to fund operations into the second half of 2025. Recent financial updates show reduced R&D and G&A expenses due to strategic restructuring, leading to a narrower net loss. The company is focused on advancing its clinical trials, with expected milestones including initial combination safety and pharmacokinetic data for SNS-101 in early 2024, followed by topline monotherapy data later in the year.
For more information, visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.
BOSTON, March 7, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics (NASDAQ: SNSE) announced the adoption of a limited duration stockholder rights agreement to protect stockholder interests. This measure is aimed at preventing any entity from gaining control without appropriately compensating all stockholders. Each stockholder will receive one preferred share purchase right for each outstanding share of common stock, effective March 17, 2023. The rights will become exercisable if an acquiring person owns 10% or more of the stock without Company approval. This plan will expire on March 7, 2024. Sensei aims to ensure its Board can make informed decisions about control attempts.
Sensei Biotherapeutics (Nasdaq: SNSE) is set to present at Oppenheimer’s 33rd Annual Healthcare Conference on March 13, 2023. The presentation will begin at 8:00 a.m. ET and be accessible via a webcast on the company’s website. The webcast replay will be available for around 90 days after the event.
Sensei Biotherapeutics focuses on developing next-generation immuno-oncology therapeutics for cancer treatment, with its lead candidate being SNS-101, designed to target the VISTA checkpoint within tumor microenvironments. The company also works on candidates SNS-102 and SNS-103, aimed at different immunosuppressive signals.
Sensei Biotherapeutics (NASDAQ: SNSE) presented preclinical data on SNS-101, a VISTA-blocking antibody, revealing its potential to enhance anti-tumor effects while reducing risks associated with other VISTA antibodies. The new crystal structure data shows that SNS-101 effectively blocks the interaction between VISTA and PSGL-1 in a pH-dependent manner. Preclinical studies indicate a decreased risk of cytokine release syndrome and improved pharmacokinetics. The company plans to submit an IND application for SNS-101 by April 2023, with a Phase 1/2 trial expected to begin later in the year, pending regulatory approval.
Sensei Biotherapeutics, a leader in immuno-oncology, announced the participation of its management team in a fireside chat at the Citi 2023 Virtual Oncology Leadership Summit on February 23, 2023, at 11:00 a.m. ET. The event highlights Sensei's innovative approaches in developing next-generation therapeutics for cancer, notably through its TMAb™ platform that aims to enhance T cell activity against tumors. Interested parties can access a live webcast of the presentation, which will also be available for replay on the company’s website for 90 days post-event. Sensei’s lead candidate is SNS-101, targeting the VISTA checkpoint.
Sensei Biotherapeutics (Nasdaq: SNSE) announced the presentation of new preclinical data on SNS-101, a VISTA-blocking antibody, at the Next Generation Antibody Therapeutics conference in Banff from February 19-22, 2023. The Chief Scientific Officer, Dr. Edward van der Horst, will present findings indicating that SNS-101 enhances the effects of PD-1 blockade in cancer treatment and showcases favorable pharmacokinetics. A poster will also be presented during the conference, providing further insights on the therapeutic's performance. The company continues to advance its TMAb™ platform for developing innovative cancer therapies.
Sensei Biotherapeutics (Nasdaq: SNSE) announced a Cooperative Research and Development Agreement with the National Cancer Institute (NCI) to advance the development of SNS-101, a pH-selective VISTA-blocking antibody. This collaboration will focus on preclinical studies to explore SNS-101's mechanisms in combination with new therapies, targeting immune checkpoint resistance.
Sensei plans to submit an IND application for SNS-101 by April 2023, with clinical trials expected to start later in the year, subject to regulatory approval. The collaboration aims to validate the efficacy and safety of SNS-101.
Sensei Biotherapeutics (Nasdaq: SNSE) has entered a clinical supply agreement with Regeneron for its anti-PD1 therapy Libtayo® (cemiplimab) to support a Phase 1/2 trial evaluating SNS-101, a VISTA-blocking antibody. The trial, aimed at solid tumors, will begin in 2023, pending regulatory approval. Sensei plans to submit an Investigational New Drug application by April 2023. This collaboration aims to explore the potential of SNS-101 combined with PD-1 inhibition, leveraging preclinical data suggesting strong anti-tumor activity.
eSensei Biotherapeutics (Nasdaq: SNSE) announces the closure of its Boston research site, resulting in a 40% workforce reduction, aimed at decreasing operating expenses. This strategic move is expected to extend the company's cash runway into the second half of 2025. The IND submission for their lead antibody, SNS-101, is anticipated by April 2023. The company will maintain its Rockville, Maryland facility to support ongoing programs, including SNS-101, designed to target the immune checkpoint VISTA.
Sensei Biotherapeutics (NASDAQ: SNSE) announced that CEO John Celebi will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, at 2:00 p.m. ET in New York. The event will focus on the company's innovative therapeutics for cancer, specifically the TMAb™ platform, which aims to activate immune responses in the tumor microenvironment. A webcast of the presentation will be available on their website, with a replay accessible for 90 days post-event.
Sensei Biotherapeutics (Nasdaq: SNSE) has presented promising preclinical data for its antibody candidate SNS-101 at the Society for Immunotherapy of Cancer annual meeting. This highly pH-selective antibody targets VISTA, showing significant anti-tumor effects and favorable pharmacokinetics. Additionally, the company is advancing its SNS-102 program, focusing on VSIG4, with plans for an IND filing for SNS-101 in the first half of 2023. Both programs leverage Sensei’s TMAb™ platform aimed at improving cancer therapies.
FAQ
What is the current stock price of Sensei Biotherapeutics (SNSE)?
What is the market cap of Sensei Biotherapeutics (SNSE)?
What is Sensei Biotherapeutics, Inc.?
What products is Sensei developing?
What is SNS-101?
What are the recent achievements of the company?
Where is Sensei Biotherapeutics headquartered?
What is the TMAb™ platform?
What financial status does Sensei Biotherapeutics have?
Who are Sensei's key collaborators?
What are the anticipated milestones for SNS-101?
Where can I find more information about Sensei Biotherapeutics?
